settingsJavascript is not enabled in your browser! This website uses it to optimize the user's browsing experience. If it is not enabled, in addition to causing some web page functions to not operate properly, browsing performance will also be poor!
Yibian
 Shen Yaozi 
home
search
AD
diseaseAbdominal Migraine Syndrome
aliasAbdominal Apoplexy Syndrome
smart_toy
bubble_chart Overview

Abdominal migraine syndrome (Abdominal Apoplexy Syndrome) is a rare type of headache. There is often a family history of migraine.

bubble_chart Clinical Manifestations

The clinical presentation includes episodic abdominal pain, lasting from a few minutes to several days. The abdominal pain may occur simultaneously with migraine, or the abdominal pain may appear without migraine, or the two may alternate. During an episode, symptoms may include fever, chills, nausea, vomiting, and/or diarrhea, profuse sweating, pale or dark red skin, along with fatigue. It is sometimes misdiagnosed as gastroenteritis, pancreatitis, appendicitis, etc., but examinations reveal no organic sexually transmitted disease. Between episodes, the patient is entirely normal.

bubble_chart Treatment Measures

During acute attacks, ergotamine is effective for treatment. For episodic abdominal pain and/or migraine, take 1-2 tablets orally (0.5-1mg per tablet), and if necessary, repeat 1-2 tablets every 0.5-1 hours, but do not exceed 6 tablets per single episode or 12 tablets per week. Overdose may cause nausea, vomiting, abdominal pain, myalgia, or peripheral ischemia as side effects. Pregnancy, coronary heart disease, hypertension, and liver or kidney diseases are contraindications due to its direct vasoconstrictive effects.

The mechanism of propranolol's effect on migraine is unclear, but 69-72% of patients benefit from its use, with about one-third experiencing a reduction in attack frequency by more than half. The usual dosage is 30-120mg/day. Pizotifen blocks 5-HT receptors and also has antihistamine, anticholinergic, and antibradykinin effects, being effective for 70% of patients during the attack stage.

AD
expand_less